CYAD-01 is a natural killer group 2D (NKG2D)-based CAR T-cell product. David Sallman, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, discusses the latest results from the completed dose-escalation of the hematological arm of the phase I THINK study (NCT03018405), which evaluated the safety and clinical activity of multiple infusions CYAD‑01 without any prior preconditioning chemotherapy in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.